Trial reportJournal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research2017
Octreotide Is Ineffective in Treating Tumor-Induced Osteomalacia: Results of a Short-Term Therapy.
Trial report in Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.
- Persistence and recurrence in tumor-induced osteomalacia: A systematic review of the literature and results from a national survey/case series.Endocrine · 2022Pooled it
- Surgical treatment as a key determinant of outcome in phosphaturic mesenchymal tumors of the bone and soft tissue: a systematic review and case series.EFORT open reviews · 2025Article
- X-linked hypophosphatemia and tumor-induced osteomalacia: a narrative review and expert opinion on the diagnostic and therapeutic challenges in the era of burosumab.Orphanet journal of rare diseases · 2025Review
- Treatment Advances in Tumor-Induced Osteomalacia.Calcified tissue international · 2025Review
- Preoperative evaluation and orthopedic surgical strategies for tumor-induced osteomalacia.Journal of bone oncology · 2024Review
- Tumor-induced osteomalacia: a case report.Journal of medical case reports · 2022Article
- Tumor-Induced Osteomalacia.Calcified tissue international · 2021Review
- Tumor induced osteomalacia in head and neck region: single center experience and systematic review.Endocrine connections · 2019Article
- Tumor-induced osteomalacia: experience from three tertiary care centers in India.Endocrine connections · 2019Article
- Tumor-induced osteomalacia.Osteoporosis and sarcopenia · 2018Review
- [Osteomalacia-Clinical aspects, diagnostics and treatment].Zeitschrift fur Rheumatologie · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
Abstract
Tumor-induced osteomalacia (TIO) is a rare paraneoplastic syndrome in which unregulated hypersecretion of fibroblast growth factor 23 (FGF23) by phosphaturic mesenchymal tumors (PMT) causes renal phosphate wasting, hypophosphatemia, and osteomalacia. The resulting mineral homeostasis abnormalities and skeletal manifestations can be reversed with surgical resection of the tumor. Unfortunately, PMTs are often difficult to locate, and medical treatment with oral phosphate and vitamin D analogues is either insufficient to manage the disease or not tolerated. Octreotide has been proposed as a potential treatment for TIO due to the presence of somatostatin receptors (SSTR) on PMTs; however, the role of somatostatin signaling in PMTs and the efficacy of treatment of TIOs with somatostatin analogues is not clear. In an effort to evaluate the efficacy of octreotide therapy in TIO, five subjects with TIO were treated with octreotide for 3 days. Blood intact FGF23, phosphate, and 1,25(OH)
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.